Irlanda - engleză - HPRA (Health Products Regulatory Authority)

bluefish pharmaceuticals ab - sunitinib - capsule, hard - sunitinib

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

bluefish pharmaceuticals ab - sunitinib - capsule, hard - sunitinib

Irlanda - engleză - HPRA (Health Products Regulatory Authority)

bluefish pharmaceuticals ab - sunitinib - capsule, hard - sunitinib

Uniunea Europeană - engleză - EMA (European Medicines Agency)

united therapeutics europe ltd - dinutuximab - neuroblastoma - antineoplastic agents - unituxin is indicated for the treatment of high-risk neuroblastoma in patients aged 12 months to 17years, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and autologous stem cell transplantation (asct). it is administered in combination with granulocyte-macrophage colony-stimulating factor (gm-csf), interleukin-2 (il-2), and isotretinoin.

Australia - engleză - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - fentanyl, quantity: 6.3 mg - drug delivery system, transdermal - excipient ingredients: polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; 2,2'-azobisisobutyronitrile; 2-hydroxyethyl acrylate - for the management of pain associated with cancer, palliative cancer and other conditions in patients where: - other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and - the pain is opioid-responsive, and - severe enough to require daily, continuous long term opioid treatment. not for use in opioid-naive patients.

Regatul Unit - engleză - MHRA (Medicines & Healthcare Products Regulatory Agency)

fdc international ltd - brimonidine tartrate - eye drops - 2mg/1ml

Tanzania - engleză - Tanzania Medicinces & Medical Devices Authority

rapid labs ltd, united kingdom - multi parameter drugs of abuse rapid test -

Australia - engleză - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - sunitinib malate, quantity: 66.825 mg (equivalent: sunitinib, qty 50 mg) - capsule, hard - excipient ingredients: gelatin; mannitol; magnesium stearate; titanium dioxide; purified water; croscarmellose sodium; povidone; iron oxide yellow; iron oxide black; iron oxide red; propylene glycol; butan-1-ol; isopropyl alcohol; shellac; ethanol absolute; ammonia; potassium hydroxide - sunitinib sun is indicated for:,? treatment of advanced renal cell carcinoma (rcc),? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance,? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

Australia - engleză - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - sunitinib malate, quantity: 50.119 mg (equivalent: sunitinib, qty 37.5 mg) - capsule, hard - excipient ingredients: gelatin; mannitol; magnesium stearate; titanium dioxide; purified water; croscarmellose sodium; povidone; iron oxide yellow; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - sunitinib sun is indicated for:,? treatment of advanced renal cell carcinoma (rcc),? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance,? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).

Australia - engleză - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - sunitinib malate, quantity: 33.413 mg (equivalent: sunitinib, qty 25 mg) - capsule, hard - excipient ingredients: gelatin; mannitol; magnesium stearate; iron oxide red; titanium dioxide; purified water; croscarmellose sodium; povidone; iron oxide yellow; iron oxide black; propylene glycol; butan-1-ol; isopropyl alcohol; shellac; ethanol absolute; ammonia; potassium hydroxide - sunitinib sun is indicated for:,? treatment of advanced renal cell carcinoma (rcc),? treatment of gastrointestinal stromal tumour (gist) after failure of imatinib mesilate treatment due to resistance or intolerance,? treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic net).